GlycoNex (ROCO:4168) Operating Margin %: -2,058.21% (As of Dec. 2025)


ROCO:4168 GlycoNex Inc ROCO:4168
56 GF Score
Price NT$24.60
GF Value NT$74.21
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is GlycoNex Operating Margin %?

GlycoNex ROCO:4168 -4.65% 56 Operating Margin % is -2,058.21% as of Dec. 2025. GuruFocus rates ROCO:4168 with a GF Score™ of 56/100 and a GF Value™ of NT$74.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, GlycoNex ranks worse than 73.73% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. GlycoNex's Operating Income for the three months ended in Dec. 2025 was NT$-90.66 Mil. GlycoNex's Revenue for the three months ended in Dec. 2025 was NT$4.41 Mil. Therefore, GlycoNex's Operating Margin % for the quarter that ended in Dec. 2025 was -2,058.21%.

Good Sign:

GlycoNex Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for GlycoNex's Operating Margin % or its related term are showing as below:

ROCO:4168' s Operating Margin % Range Over the Past 10 Years
Min: -47476.5   Med: -17794.61   Max: -659.81
Current: -659.81


ROCO:4168's Operating Margin % is ranked worse than
73.73% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs ROCO:4168: -659.81

GlycoNex's 5-Year Average Operating Margin % Growth Rate was 45.30% per year.

GlycoNex's Operating Income for the three months ended in Dec. 2025 was NT$-90.66 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-249.81 Mil.


GlycoNex  (ROCO:4168) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


GlycoNex Operating Margin % Related Terms


GlycoNex Operating Margin % Historical Data

* Premium members only.

The historical data trend for GlycoNex's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex Operating Margin % Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,560.33 -793.22 -10,222.82 -1,674.14 -659.81

GlycoNex Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,021.05 -382.50 -231.00 -1,822.48 -2,058.21

ROCO:4168 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, GlycoNex's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Operating Margin % distribution charts can be found below:

* The bar in red indicates where GlycoNex's Operating Margin % falls into.


ROCO:4168
56GF Score
GlycoNex Inc ROCO:4168
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlycoNex Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

GlycoNex's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-249.809 / 37.861
=-659.81 %

GlycoNex's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-90.664 / 4.405
=-2,058.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -2,058.21% mean?
GlycoNex (ROCO:4168) has a Operating Margin % of -2,058.21% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #696 out of 944 companies in the Biotechnology industry, placing it in the top 73.7%.
Is GlycoNex's Operating Margin % too high?
GlycoNex's current Operating Margin % is -2,058.21%. Based on the distribution chart, GlycoNex ranks #696 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #696 out of 944 companies for Operating Margin %. This places GlycoNex in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on GlycoNex and its competitors. GlycoNex's current Operating Margin % is -2,058.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.21, compared to a current price of NT$24.60 — trading 66.9% below its estimated fair value. The current Operating Margin % is -2,058.21%. GlycoNex's overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Operating Margin % is -2,058.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$24.60 is trading 66.9% below its estimated GF Value™ of NT$74.21. GuruFocus considers GlycoNex to be Significantly Undervalued.

Key valuation signals for ROCO:4168:

  • Operating Margin %: -2,058.21%
  • GF Value™: NT$74.21 vs. price of NT$24.60 (66.9% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score

Get the complete analysis for ROCO:4168

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.60
Price
NT$74.21
GF Value